Rux is a cyclin-dependent kinase inhibitor (CKI) specific for mitotic cyclin–Cdk complexes  by Foley, Edan et al.
1392 Research Paper
Rux is a cyclin-dependent kinase inhibitor (CKI) specific for
mitotic cyclin–Cdk complexes 
Edan Foley*, Patrick H. O'Farrell† and Frank Sprenger*
Background: Roughex (Rux) is a cell-cycle regulator that contributes to the
establishment and maintenance of the G1 state in the fruit fly Drosophila.
Genetic data show that Rux inhibits the S-phase function of the cyclin A
(CycA)–cyclin-dependent kinase 1 (Cdk1) complex; in addition, it can prevent
the mitotic functions of CycA and CycB when overexpressed. Rux has no
homology to known Cdk inhibitors (CKIs), and the molecular mechanism of Rux
function is not known.
Results: Rux interacted with CycA and CycB in coprecipitation experiments.
Expression of Rux caused nuclear translocation of CycA and CycB, and
inhibited Cdk1 but not Cdk2 kinase activity. Cdk1 inhibition by Rux did not rely
on inhibitory phosphorylation, disruption of cyclin–Cdk complex formation or
changes in subcellular localization. Rux inhibited Cdk1 kinase in two ways: Rux
prevented the activating phosphorylation on Cdk1 and also inhibited activated
Cdk1 complexes. Surprisingly, Rux had a stimulating effect on CycA–Cdk1
activity when present in low concentrations.
Conclusions: Rux fulfils all the criteria for a CKI. This is the first description in a
multicellular organism of a CKI that specifically inhibits mitotic cyclin–Cdk
complexes. This function of Rux is required for the G1 state and male meiosis
and could also be involved in mitotic regulation, while the stimulating effect of
Rux might assist in any S-phase function of CycA–Cdk1.
Background
Cell-cycle progression is controlled by cyclin-dependent
kinases (Cdks) [1]. Downregulation of Cdk activity can
occur by inhibitory phosphorylation, cyclin proteolysis or
through the action of Cdk inhibitors (CKIs) [2,3]. CKIs
mediate cell-cycle arrest at specific stages by acting on
Cdks, cyclins or cyclin (Cyc)–Cdk complexes. In higher
eukaryotes, there are two distinct families of CKIs, the
p21Kip/p27Cip family and the INK4 family of inhibitors [3].
Both inhibit S-phase-promoting Cdk activity, thereby
safeguarding the stability of G1. CKI targets are com-
plexes consisting of G1 cyclins with Cdk2, Cdk4 or Cdk6
[4–7]. No inhibitors of Cyc–Cdk1 complexes have been
described so far in higher eukaryotes. 
In Drosophila, a single CKI, Dacapo, has been identified that
belongs to the p21/p27 class of CKIs [8,9]. Dacapo is
required for the establishment of the first G1 state of embry-
onic development during cycle 17. It binds CycE–Cdk2 and
inhibits kinase activity in vivo and in vitro [8]. Dacapo is also
required at later stages, for example during eye develop-
ment, for the establishment and maintenance of G1 [9].
Although CycE–Cdk2 is the main S-phase inducer in
Drosophila, CycA–Cdk1 is also able to trigger a G1–S tran-
sition [10]. For the establishment and maintenance of the
G1 state, CycA–Cdk1 activity must therefore be downreg-
ulated as well. During Drosophila embryogenesis, this
S-phase function of CycA is normally suppressed in G1 by
at least three different mechanisms: inhibitory phosphory-
lation of Ckd1, CycA instability during G1 and the activity
of Roughex (Rux) [10].
The rux gene was initially identified in a screen for muta-
tions affecting development of the Drosophila eye [11].
During eye development, cells are synchronized in G1 in
the morphogenetic furrow where neuronal differentiation
is initiated. In rux mutants, this critical G1 phase is not
established and cells undergo a premature S phase. Muta-
tions in rux also cause reduced viability and male sterility
[11,12]. During spermatogenesis, rux germ cells go
through meiosis I and II but then attempt an additional
aberrant division, resulting in aneuploid nuclei. The rux
phenotypes are dominantly suppressed by mutations in
cycA and genes encoding the Drosophila CDC25 homologs,
string and twine [11,12]. A genetic interaction between cycA
and rux can also be demonstrated when both genes are
overexpressed: the expression of CycA can induce ectopic
S phases but the simultaneous expression of Rux inhibits
these S phases [10,13]. By contrast, S phases that are trig-
gered by CycE–Cdk2 activity are not prevented when
Rux is overexpressed [13]. This indicates that Rux is not a
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general S-phase suppressor, but that it specifically pre-
vents CycA-associated S-phase activity. In addition, when
Rux is expressed during S or G2, Cdk1-dependent
mitoses are inhibited [13]. At the cellular level, both
effects of Rux are associated with a change in the subcel-
lular distribution of the mitotic cyclins CycA and CycB.
Normally, both cyclins are present in the cytoplasm during
interphase; during prophase they accumulate in the
nucleus and are degraded during mitosis [14,15]. In G1,
turnover of mitotic cyclins is high and only very low levels
can be detected. When Rux is overexpressed in G1
together with CycA, a transient nuclear localization can be
observed, followed by degradation of CycA [13]. When
Rux is expressed during S and G2 or if the rux gene dose
is increased during spermatogenesis, CycA is again
translocated to the nucleus [11,12].
All of the above data suggest that Rux acts by inhibiting
mitotic Cyc–Cdk activity. Rux shares no homology to any
other CKI or other proteins in the sequence databases,
however, nor have any molecular interactions between
CycA and Rux been demonstrated. Rux does interact with
CycE in vitro and in a yeast two-hybrid system and is
phosphorylated by CycE–Cdk2 in vitro. Overexpression of
CycE results in degradation of Rux, suggesting that phos-
phorylation of Rux by CycE–Cdk2 activity at the G1–S
transition targets Rux for degradation [13]. The failure to
detect any direct association between Rux and CycA in
vitro and the lack of homology to known CKIs led to the
suggestion that Rux itself is not a CKI but, rather, pro-
motes the activities of an unknown CKI [10,13].
Here, we provide evidence that Rux is a CKI. We found
that CycA and CycB associate with Rux in vivo. The
expression of Rux in embryos resulted in a strong reduction
of Cdk1 kinase activity. This inhibition of kinase activity
was independent of inhibitory phosphorylation of Cdk1. In
vitro analysis demonstrated that Rux prevents the activat-
ing phosphorylation of Cdk1 on Thr161 and that Rux also
inhibits Cdk1 activity by other means. Interestingly, Rux
had a dual effect on CycA-associated kinase activity, result-
ing in activation of kinase activity at lower concentrations
and inhibition at higher concentrations. These data indi-
cate that Rux is a novel CKI that is present in a higher
eukaryote and acts specifically on mitotic cyclins.
Results
Rux subcellular localization, its effect on cyclin localization
and mitotic progression
As a tool to study protein interaction, we developed a Rux
antibody (see Materials and methods). On western blots, it
specifically recognized in vitro translated Rux protein and
detected a specific band in 3–6 hour old embryos after Rux
expression from a heat-inducible promoter (data not
shown). In extracts from wild-type embryos of this stage, no
Rux band was detected, consistent with the low abundance
of Rux mRNA. To determine the subcellular localization of
Rux, we performed indirect immunofluorescent labeling of
embryos after heat-induced expression of Rux (Figure 1c,e)
and after injection of mRNA coding for a haemagglutinin
(HA)-tagged Rux (HA–Rux, Figure 1i,k). In both cases, a
nuclear staining was observed, consistent with previous
findings [13]. We identified a bipartite nuclear localization
sequence (NLS; Figure 1h) at the carboxyl terminus of
Rux, and created a deletion of HA–Rux lacking the last
13 amino acids (HA–Rux∆NLS), including the second
basic cluster of the putative NLS. Immunofluorescent
labeling of embryos after injection of HA–Rux∆NLS
mRNA now showed a predominantly cytoplasmic staining
of Rux (Figure 1p,r), indicating that the identified NLS is
required for the normal nuclear localization of Rux.
Rux expression causes nuclear accumulation of mitotic
cyclins [10,13]. Using our Rux antibodies, we could now
determine whether Rux and mitotic cyclins occupy identi-
cal compartments within the cell. We found that Rux
overexpression caused CycA accumulation in the nucleus
(Figure 1d). Rux and CycA both occupied most of the
nuclear space but were excluded from the nucleolus
(Figure 1e–g). Although most of the Rux staining was
restricted to the nucleus, we found that a proportion of
CycA remained in the cytoplasm. On the other hand,
when we expressed HA–Rux∆NLS, both Rux and CycA
remained cytoplasmic (Figure 1p–v), showing that nuclear
localization of Rux is required for the induced nuclear
accumulation of CycA.
In cycles 14–16 of Drosophila embryogenesis, Cdk1 is
held in an inactive state throughout S phase and G2 by
inhibitory phosphorylations [16]. Controlled expression of
Cdc25String phosphatase relieves these inhibitory con-
straints and induces mitosis in a complex spatial and tem-
poral pattern. Mitotic progression can be monitored by
the turnover of CycA, which is degraded in each mitosis
in a stereotypical pattern (Figure 1a,b). After expression
of Rux, no CycA turnover could be observed (Figure 1d),
indicating that cells are prevented from undergoing
mitosis. The absence of other mitotic markers (tubulin,
condensed DNA or phosphorylated histone H3; data not
shown) indicated that cells are blocked at a pre-mitotic
step, most likely in a G2-like state. In embryos in which
Rux was locally expressed by mRNA injection, we also
observed a lack of mitotic progression in regions with
high Rux levels, but normal mitotic pattern of CycA
degradation in regions that have little or no Rux levels
(Figure 1j). A lack of a normal mitotic pattern was also
observed when HA–Rux∆NLS mRNA was injected into
embryos. In the embryo shown in Figure 1q, the normal
bilaterally occurring mitoses are blocked on the side of
the embryos with high levels of HA–Rux∆NLS, whereas
CycA degradation and, thus, mitotic progression occurs
on the opposing side.
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In summary, Rux, a nuclear protein, causes CycA localiza-
tion to the nucleus and prevents entry into mitosis. The
nuclear localization of Rux and CycA requires a functional
NLS at the carboxyl terminus of Rux. In its absence, Rux
remains predominantly cytoplasmic and no nuclear accu-
mulation of CycA is observed. Nevertheless, Rux lacking
the NLS is still able to inhibit mitosis, indicating that this
effect of Rux does not require a nuclear localization.
Rux interacts with mitotic cyclins and causes inhibition of
Cdk1 activity
The overlapping localization of CycA with Rux and
Rux∆NLS raises the possibility that both proteins physi-
cally associate. To test whether Rux associates with
cyclins in vivo, we performed immunoprecipitations from
embryonic extracts, using Rux antiserum and looked for
coprecipitation of cyclins and Cdk1. Using extracts from
3–5 hour hs–rux embryos, we immunoprecipitated Rux
and could detect coprecipitation of CycA, CycB and, to a
lesser extent, Cdk1 (Figure 2a,b). Rux did not precipitate
control proteins like Even-skipped or β-tubulin (Figure 2a
and data not shown).
To determine what consequence the interaction of Rux
with mitotic cyclins has on Cdk1 kinase activity, we precipi-
tated Cdk1 from embryonic extracts and determined its
kinase activity using histone H1 as a substrate. High kinase
activity levels were found in wild-type embryos (Figure 2c),
which increased several fold upon CycA induction (hs-cycA;
Figure 2c). The expression of Rux in either of these two sit-
uations led to a decrease in Cdk1 kinase activity
(Figure 2c). Similar amounts of Cdk1 were precipitated in
all four cases (Figure 2c, PSTAIRE immunoblot). 
Inhibition of Cdk1 kinase activity can occur at multiple
levels, including inhibitory phosphorylation of Cdk1 on
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Rux is a nuclear protein that causes CycA accumulation in the nucleus
and prevents mitosis. (a,b) CycA staining pattern in a wild-type embryo
undergoing the 14th division cycle, revealing the normal mitotic
pattern. (b) Magnified view of the boxed region in (a), stained for DNA
(red) and CycA (cyan). Note the predominantly cytoplasmic staining in
interphase cells (upper right corner) and the mitotic degradation of
CycA starting in metaphase. (c–g) Staining of (c) Rux and (d) CycA in
a 14th cell-cycle embryo after expression of Rux from a heat-shock
transgene (hs–rux). The mitotic pattern of CycA turnover is absent.
(e–g) High magnification views of amnioserosa cells (boxed in panels c
and d). (f,g) CycA and (e,f) Rux colocalize in the nucleus, while CycA is
also present in the cytoplasm. (h) Comparison of the Rux sequence
commencing at amino-acid position 308 with the consensus sequence
for bipartite NLSs [43] and the sequence of the Rux∆NLS construct
(a stop codon was introduced at the position marked with an asterisk).
(i–o) Expression and subcellular localization of (i) HA–Rux and
(j) CycA in embryos injected at the anterior end with HA–Rux mRNA.
High levels of (i) HA staining can be observed in the head region
where mitotic degradation of (j) CycA is blocked. Normal turnover of
CycA can be seen in the remainder of the embryo where HA–Rux is
absent. (k–o) High magnification views of cells marked in (i,j), showing
nuclear localization of (k) Rux, (l) CycA and (m) DNA, and (n) merged
Rux and CycA staining and (o) merged Rux and DNA staining.
(p,q) Embryo injected with mRNA encoding HA–Rux∆NLS. (p) High
levels of HA–Rux∆NLS can be seen in the posterior region on one side
of the embryo. In this region, mitotic progression is blocked, as
visualized by (q) the lack of CycA turnover. (r–v) High magnification
views of cells marked in (p,q) showing cytoplasmic localization of
(r) Rux∆NLS, (s) CycA and (t) nuclear DNA, as well as (u) merged Rux
and CycA staining and (v) merged Rux and DNA staining.
Thr14 and Tyr15 [1]. To test whether Rux inhibits Cdk1
activity by modulating Thr14 and Tyr15 phosphorylation,
we expressed a mutant form of Cdk1 in which the Thr14
and Tyr15 residues were substituted with Ala and Phe and,
thus, cannot be phosphorylated on these residues
(Cdc2AF). A simultaneous overexpression of Cdc2AF and
CycA (hs–Cdc2AF;hs-cycA) was sufficient to induce mitosis
throughout the entire embryo (Figure 2e). The coexpres-
sion of Rux prevented mitosis in most cells of the embryo
(Figure 2f), however, demonstrating that the effect Rux
does not rely on the Thr14 and Tyr15 phosphorylation
state of Cdk1. In the absence of Thr14 and Tyr15 phos-
phorylation of Cdc2AF, the only phosphoisoform is the
Thr161-phosphorylated form. This isoform shows a higher
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Rux binds CycA and CycB and inhibits Cdk1 kinase activity. 
(a,b) Rux coimmunoprecipitates mitotic cyclins and Cdk1. Wild-type
(WT) and hs–rux embryonic extracts were immunoprecipitated (IP)
with normal rat serum (NRS) or Rux antibodies and analyzed on
western blots using antibodies against CycA, CycB, Even-skipped and
the PSTAIRE motif. As a control, the extract was blotted with the
respective antibodies to indicate the position of the relevant antigens
(asterisks). In extracts, CycA migrates as a doublet, the band below
the doublet is a cross-reacting band. Arrowheads, position of the
immunoglobulin heavy and light chains. The secondary antibody used
to detect the CycA primary antibody only recognizes light chain from
the rat serum. (c) Cdk1 kinase activity is reduced after Rux expression.
Extracts were made from 4–6 h old wild-type (lanes 1,5), hs–cycA
(lanes 2,6), hs–cycA;hs–rux (lanes 3,7), and hs–rux (lanes 4,8)
embryos. Precipitation was performed using normal rabbit serum
(mock, lanes 1–4) or with Cdk1 antiserum (lanes 5–8). Kinase activity
of wild-type embryos was set to 100%. Expression of cycA (lane 6)
resulted in a sevenfold stimulation of kinase activity towards histone
H1. Expression of rux (lane 8) caused reduction of kinase levels to half
that found in the wild type; in embryos expressing cycA and rux (lane
7), levels were reduced to a seventh of those for embryos expressing
CycA alone (lane 6). (d) Rux can suppress kinase activity of Cdc2AF,
a mutant form of Cdk1 that lacks inhibitory phosphorylation sites.
Extracts from heat-shocked hs–cycA;hs–Cdc2AF and
hs–cycA;hs–Cdc2AF;hs–rux embryos were precipitated with Cdk1
antiserum and either blotted for the PSTAIRE western blot or used for
the kinase assay with histone H1 as a substrate. The expression of Rux
reduced total kinase levels to 40%. In the PSTAIRE western blot,
several isoforms of Cdk1 could be detected, which derive from both
endogenous, wild-type Cdk1 and Cdc2AF. The latter only comes in two
forms, unphosphorylated and Thr161-phosphorylated. The majority of
the wild-type Cdk1 is Thr14 and Tyr15 phosphorylated at this stage of
embryogenesis and migrates with slower electrophoretic mobility. The
bulk of the fastest migrating form is the Thr161-phosphorylated form of
Cdc2AF (arrowhead). The coexpression of Rux led to a marked
reduction in the levels of this phosphoisoform. (e,f) CycA staining in
(e) hs–cycA;hs–Cdc2AF and (f) hs–cycA;hs–Cdc2AF;hs–rux embryos.
Rux inhibited progression through mitosis, independent of inhibitory
phosphorylations. Coexpression of CycA and Cdc2AF overran the
normal mitotic pattern of cell division 14 in the embryos and induced
simultaneous mitoses throughout the embryo. This resulted in a mitotic
degradation of CycA in most of the cells in (e). Simultaneous
expression of Rux prevented the execution of mitosis, visualized in (f)
by the persistence of CycA staining in most cells.
electrophoretic mobility than unphosphorylated Cdk1 on
SDS–PAGE [17] and can readily be detected when Cdc2AF
and CycA are coexpressed. The simultaneous expression
of Rux led to a drastic reduction in the levels of this phos-
phoisoform and a corresponding decrease in kinase activity
towards histone H1 (Figure 2d).
In conclusion, we observe an interaction of Rux with
mitotic cyclins and a downregulation of Cdk1 activity.
This inhibition is not mediated by inhibitory phosphoryla-
tion on Thr14 and Tyr15. We observe a significant reduc-
tion in the level of Thr161 phosphorylation on Cdk1,
however, suggesting that Rux can modulate the Thr161
phosphorylation state of Cdk1.
Rux inhibits mitotic cyclins in vitro
To analyze Rux-dependent Cdk regulation in greater
detail, we used an in vitro system that enabled us to
analyze Cyc–Cdk complexes, permitted the addition of
Rux at different steps of the Cdk activation process and
allowed analysis of Cdk activation and activity. The pro-
teins used were translated individually in reticulocyte
lysate in the presence of [35S]Met (Figure 3a). We used
HA-tagged Cdks to facilitate immunoprecipitation and
amino-terminally truncated forms of mitotic cyclins
(CycA∆170 and CycB∆46), which are more stable in our
system. Cdk activation requires phosphorylation of
Thr161 (Thr163 in Cdk2) by a Cdk-activating kinase
(CAK) [18]. We used an embryonic extract from 0–1 hour
old embryos as a source of CAK (‘extract’). This extract
contains few free cyclins, which would interfere with our
assay, and does not phosphorylate Cdk1 on Thr14 or
Tyr15 [19]. The CAK in this extract is likely to be of the
CycH–Cdk7 type, as extracts from cdk7 mutants fail to
provide CAK activity (data not shown and [20]). After
immunoprecipitation of HA–Cdks, kinase activity was
measured using histone H1 as a substrate. In addition, a
fraction of the immunoprecipitate was used to monitor
Thr161 phosphorylation of Cdk1 by high-resolution
SDS–PAGE (Figure 3c).
Incubation of reticulocyte-translated HA–Cdk1 or
HA–Cdk2 with Drosophila extract alone did not result in
significant Cdk activity (Figure 3d,e; lanes 1,6). Cdk acti-
vation was achieved by adding cyclin (lanes 2,4,7). The
extent of activation varied for the different cyclins used,
probably reflecting their different affinities for their Cdk
partners. The presence of Rux in this system had a strong
inhibitory effect on Cdk1 kinase activity, reducing the
level of histone H1 phosphorylation to almost back-
ground levels (lanes 3,5). Both cases of inhibition dis-
played a corresponding decrease in the extent of Thr161
phosphorylation on Cdk1 (Figure 3c; lanes 3,5). In con-
trast, no significant change in the kinase activity of Cdk2
was observed (lane 8). This experiment was repeated
three times, with similar results obtained each time.
These data demonstrate that Rux specifically inhibits
mitotic Cyc–Cdk1 activity, but does not inhibit
CycE–Cdk2 activity. Using a Rux fusion protein tagged
at the amino terminus with glutathione-S-transferase
(GST), we did not observe any effects on Cdk1 activity.
The addition of GST to the amino terminus might abro-
gate Rux function and could explain the failure of previ-
ous attempts to show inhibition of CycA-dependent
kinase activity by Rux in vitro [13].
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Rux is a specific inhibitor of mitotic cyclins. (a) Autoradiogram of
35S-labeled reticulocyte-translated proteins. (b–e) Immune-complex
kinase assay of various cyclin–Cdk complexes in the absence or
presence of Rux using histone H1 as substrate. Drosophila extract
was used as a source of CAK. Immunoprecipitation was done using
antibodies against the HA tag on Cdk1 and Cdk2. The presence of
Rux reduced kinase activity of CycA–Cdk1 and CycB–Cdk1 but not
that of CycE–Cdk2. (b) ‘Input gel’ showing presence and abundance
of the different translation products in the individual experimental
samples. (c) Phosphorylation state of the immunoprecipitated Cdks.
Autoradiogram of a high-resolution SDS–PAGE to visualize the level
of Thr161 and Thr163 phosphorylation of Cdk1 and Cdk2,
respectively. Only the molecular weight range between 28 and 38
kDa is shown. (d) Autoradiogram after histone H1 phosphorylation
and high-resolution SDS–PAGE. The 32P-labelled histone H1 signal
appears as two blocks. The sharp bands above the histone H1 signal
correspond to the 35S-labeled Cdks. (e) Phosphorimaging results
from counting the 32P signal. The level of phosphorylation obtained
with CycA–Cdk1 (lane 2) was set to 100%. We do not consider the
minor increase in kinase activity between lanes 7 and 8 significant as
it is not reproducible.
Rux modulation of CycA- and CycB-dependent kinase
activity in vitro
To better analyze Rux regulation of Cdk1 kinase activity,
we monitored the effects of different doses of Rux on
CycA- and CycB-dependent kinase activity. When CycB
was used as a cyclin partner for Cdk1, we observed an
inhibition of kinase activity by Rux that increased with
increasing amounts of Rux (Figure 4d,e). Looking at the
Thr161-phosphorylated form of Cdk1, we found this
isoform to some extent even in the absence of added
CycB, which could result from the presence of free cyclins
in the extract used (Figure 4c). Addition of CycB stimu-
lated Thr161 phosphorylation but addition of Rux
resulted in a marked decrease in the abundance of this
phosphoisoform. The amount of CycB that coprecipitated
with HA–Cdk1, on the other hand, remained constant
throughout the experiment (Figure 4b).
In the above experiments, we used a crude embryonic
extract to provide CAK activity. This extract may contain
accessory Drosophila molecules that mediate the effects of
Rux. To exclude this possibility, we replaced the embry-
onic extract with a bacterially expressed GST fusion
protein containing the CAK activity from the Saccharomyces
cerevisiae CIV1 gene [21–23]. While this monomeric enzyme
shares no homology with the CycH–Cdk7 complex, it can
phosphorylate the Thr161 (or equivalent) position of
several Cdks from higher eukaryotes [22]. Using
GST–CIV1, we could activate Cdk1 in a cyclin-dependent
manner. The level of Thr161 phosphorylation on Cdk1
remained constant in this experiment. CIV1 was able to
phosphorylate monomeric Cdk1 (Figure 4h, lane 1) [22]
and we did not find a significant increase in the Thr161-
phosphorylated form after the addition of CycB. An effect
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Rux modulation of CycA- and CycB-dependent kinase activity in vitro.
(a,f,k) Levels of in vitro translated proteins used in this assay.
(b,g,l) Levels of associated cyclins and (c,h,m) level of Thr161-
phosphorylated HA–Cdk1 were visualized after SDS–PAGE and
autoradiography of the immune complexes. (d,e,i,j,n,o) Kinase assays
using histone H1 as substrate were performed after
immunoprecipitation of HA–Cdk1. (a–e) Rux inhibits CycB-dependent
Cdk1 kinase activity in a progressive fashion. Drosophila extract was
used as a source of CAK. Incubation of HA–Cdk1 with extract resulted
in some kinase activity, which was stimulated fourfold by the addition of
CycB. Increasing amounts of Rux led to a reduction of kinase activity to
one-third of the positive control. (b,c) The presence of larger amounts of
Rux consistently led to a reduction in the Thr161-phosphorylated form of
Cdk1 while no significant change in the level of CycB coprecipitation
was seen. (f–j) Rux inhibition does not require additional Drosophila
proteins and is independent of the source of CAK. Bacterially expressed
GST–CIV1 was used instead of the crude Drosophila extract as a
source of CAK. (h) GST–CIV1 was able to efficiently phosphorylate
monomeric Cdk1 (lane 1) but kinase activity still depended on adding
cyclin (lanes 1,3). Rux inhibited CycB–Cdk1 kinase activity to 43% of
the positive control (lanes 3,4). No change in (g) cyclin coprecipitation
or (h) Thr161 phosphorylation was seen. (k–o) Rux is a bimodal
regulator of CycA–Cdk1 kinase activity. (n,o) CycA-induced kinase
activity was stimulated threefold by lower concentrations of Rux (0 µl
Rux versus 1.5 µl Rux). Any further addition of Rux had an inhibitory
effect, reducing kinase levels close to background levels. (l) Levels of
CycA coprecipitating remained fairly constant. Nevertheless, a reduction
in the level of the slowest migrating phosphoisoform of CycA could be
seen. (m) The level of Thr161 phosphorylation was reduced when higher
amounts of Rux were present.
of Rux on Thr161 phosphorylation of CycB–Cdk1 com-
plexes could therefore not be detected. Addition of Rux
resulted in an inhibition of kinase activity to about 40% of
the positive control. This indicates that no additional
Drosophila proteins are required for Rux inhibition of Cdk1
kinase activity. Furthermore, because Rux can inhibit
CycB–Cdk1 activated by either extract or CIV1, we believe
that Rux does not inhibit by acting on CAK.
In contrast to the effects of Rux on CycB–Cdk1 kinase
activity, Rux had a more complex effect on CycA–Cdk1
activity. Figure 4k–o shows a typical example, which
demonstrates that Rux has a dual effect on CycA–Cdk1
activity. In this assay, the addition of CycA∆170 led to an
approximate threefold stimulation of Cdk1 kinase activity
in comparison to Cdk1 alone (Figure 4o, 0 µl Rux versus
control). Unexpectedly, the presence of small amounts of
Rux (1.5–4.5 µl) resulted in a further threefold increase in
Cdk1 kinase activity. Any further addition of Rux resulted
in a decline in Cdk1 kinase activity. The addition of 42 µl
Rux reduced Cdk1 kinase activity to less than 50% of that
for the positive control (42 µl Rux versus 0 µl Rux). This
experiment was repeated seven times and similar results
were recorded each time. Small amounts of Rux (1.5–4.5 µl)
enhanced CycA–Cdk1 activity by about 300% (± 100%),
whereas large amounts exerted a visible inhibitory effect,
reducing kinase activity to 40% (± 8%) of the positive
control. This value was similar to basal levels of Cdk1 activ-
ity in this assay. Large amounts of Rux led to a decline in
the extent of Thr161 phosphorylation, whereas the stimula-
tory effect of Rux on Cdk1 did not have a corresponding
effect on Thr161 phosphorylation (Figure 4m). No signifi-
cant change in the amount of CycA coprecipitation was
observed (Figure 4l). A similar bimodal effect of Rux on
CycA–Cdk1 was also observed when GST–CIV1 was used
instead of the Drosophila extract to activate Cdk1 (data not
shown), indicating that these effects of Rux do not require
additional Drosophila proteins. 
Rux can inhibit active Cyc–Cdk1 complexes
The inhibition of Cyc–Cdk1 complexes observed in the
previous experiments was to a certain extent associated
with a decrease in Thr161 phosphorylation of Cdk1. To
determine whether Rux can also inhibit fully activated
Cyc–Cdk1 complexes, we pre-activated Cyc–Cdk1 and
added Rux in a second incubation step. In the first set, we
used CycA–Cdk1 activated by CIV1 in reticulocyte lysates
(Figure 5a–c). Kinase activity in this experimental setup
was measured directly by taking an aliquot of the reaction
mixture (Figure 5b,c). High levels of CycA-dependent
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Figure 5
Rux can inhibit pre-activated CycA–Cdk1
complexes. (a–c) HA–Cdk1 was activated
with GST–CIV1 and CycA for 30 min before
addition of Rux or control reticulocyte lysate
(retic). (b,c) An aliquot of the protein mixture
was analyzed in a direct kinase assay using
histone H1 as substrate. Reticulocyte extract
contains low kinase levels, and neither Cdk1
nor GST–CIV1 alone stimulated kinase
activity (lanes 1,2). The combined presence of
Cdk1, CycA and GST–CIV1 resulted in high
kinase activity (lane 3). The addition of Rux
after the activation step resulted in strong
inhibition of kinase levels (lane 6). (a) After
immunoprecipitation of HA–Cdk1, Thr161
phosphorylation was analyzed by
SDS–PAGE. No change in the level of
Thr161 phosphorylation was observed.
(d–f) Rux inhibits Cdk1 activity present in
embryonic extracts. Extracts from 0–1 h old
embryos were incubated with control
reticulocyte lysate (lane 7) or HA–Rux
(reticulocyte lysate translated in the absence
of [35S]Met, lane 8), and (e,f) an aliquot of
each sample was analyzed in a direct kinase
assay using histone H1 as substrate.
(e) A control containing reticulocyte-lysate-
translated HA–Rux was loaded next to the
kinase reaction and immunoblotted with HA
antibodies to mark the position of the HA–Rux
protein (lane 9). (d) A second aliquot of the
three reactions was analyzed on a western
blot using PSTAIRE antibodies. High levels of
kinase activity towards histone H1 are present
in embryonic extracts (lane 7). The addition of
HA–Rux caused a reduction in kinase levels to
14% (lane 8). We did not observe
incorporation of radiolabeled phosphate into
HA–Rux during the kinase reaction, indicating
that HA–Rux does not act as a competitive
substrate in this reaction. (d) The analysis of
Cdk1 using the PSTAIRE antibody revealed
that Thr161 phosphorylation is not reduced by
the addition of Rux.
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kinase activity were seen (Figure 5b, lane 3). The addition
of Rux resulted in a strong inhibition of kinase activity,
however, while Thr161 phosphorylation of Cdk1 was not
affected (Figure 5b and 5a, respectively; lane 6). In the
second setup, we assayed the kinase activity of embryonic
extract from 0–1 hour old embryos. These extracts con-
tained high levels of CycB–Cdk1-dependent kinase activity
(Figure 5f, lane 7; F.S., unpublished data). This activity was
efficiently inhibited by HA–Rux (Figure 5e; compare lanes
7,8). We did not observe phosphorylation of HA–Rux under
these conditions (Figure 5e), demonstrating that HA–Rux
does not compete with the added histone H1 as a substrate
for Cdk1 phosphorylation. We also did not observe a dimin-
ishment of Thr161 phosphorylation on Cdk1 (Figure 5d)
after the addition of Rux, suggesting that the inhibition
being observed in this case is a direct inhibition of Cdk1
activity. The fact that Rux can directly inhibit Cdk1 under
both of these conditions further supports the idea that Rux
does not solely function by inhibiting CAK activity.
Discussion
Several mechanisms contribute toward maintenance of
the G1 state, including the activity of CKIs. These pro-
teins have the following characteristics (as defined in [2]):
they physically associate with a cyclin, a Cdk or both but
do not covalently modify either. CKIs downregulate Cdk
activity by inhibiting Cdk activation, its activity or both.
Here, we have presented evidence that Rux acts as a CKI
specific for Cdk1. 
A molecular interaction of Rux with mitotic cyclins was
seen in immunoprecipitation experiments. Both CycA and
CycB and, to a lesser extent, Cdk1 were coprecipitated in
Rux precipitations, indicating that Rux can form com-
plexes with cyclins and possibly with Cyc–Cdk complexes.
The interaction of a variety of proteins, including CKIs,
with cyclins is mediated by RXL motifs [24]. Rux contains
three RXL motifs, starting at positions 30, 197 and 249,
that could mediate the observed interaction of Rux with
cyclins. An association of Rux with mitotic cyclins is sup-
ported by the observed changes in subcellular localization
of cyclins upon expression of Rux. We found that a large
proportion of CycA, which is normally cytoplasmic during
interphase, moves into the nucleus and overlaps with Rux.
The Rux protein itself is nuclear and requires a functional
bipartite NLS sequence at its carboxyl terminus for its
localization. Rux∆NLS failed to localize into the nucleus
and CycA remained in the cytoplasm. The observed
nuclear accumulation of CycA after Rux expression could
thus be explained by a nuclear transport of CycA–Rux
complexes mediated by the NLS of Rux. Alternatively,
Rux could interfere with a putative nuclear export of
CycA, leading to a nuclear accumulation of CycA. 
Rux can inhibit Cdk1-dependent mitosis and CycA–Cdk1-
dependent S phases [10,13]. Here, we have presented 
evidence that the molecular basis of these effects is inhibi-
tion of CycA- and CycB-dependent Cdk1 kinase activity.
We found that Rux expression led to a marked decrease in
Cdk1 kinase activity from embryos, and we demonstrated
an inhibition of kinase activity using in vitro assembled and
activated Cyc–Cdk1 complexes. In the latter assays, both
CycA- and CycB-dependent kinase activities were sup-
pressed. Although we cannot strictly rule out the interfer-
ence of reticulocyte proteins in some of our in vitro assays,
we consider this unlikely, as the effects observed using
in vitro translated proteins were identical to those seen
using embryonic extracts. Genetic data have already indi-
cated the importance of Rux in downregulation of
CycA–Cdk1 activity during G1. The importance of inhibit-
ing CycB–Cdk1 kinase activity is less clear, as CycB is
unable to induce S phase in Drosophila [10]. Nevertheless,
the effects of Rux on mitotic Cyc–Cdk1 complexes opens
up the possibility that it may also contribute to regulating
entry into or exit from mitosis. It is interesting to note that
Sic1, a CKI from S. cerevisiae that inhibits S-phase-inducing
activity during G1 can also contribute to exit from mitosis
under certain circumstances [25]. Rux has no effect on
CycE–Cdk2 kinase activity in vitro and cannot inhibit
CycE/Cdk2-dependent S phases in vivo [10,13]. Thus,
inhibition by Rux is specific for mitotic cyclins and, like
the Sic1 inhibitor of S. cerevisiae, would help to enforce a
requirement for G1 cyclins to promote S phase.
How does Rux inhibit Cdk1 activity? Activation of Cdk1
requires cyclin association, phosphorylation of Thr161 in
the T-loop and dephosphorylation of inhibitory Thr14 and
Tyr15 phosphorylation sites. Rux inhibition does not
require modulation of the inhibitory phosphorylations.
Firstly, Rux was able to inhibit kinase activity and induc-
tion of mitosis by Cdc2AF, a mutant form of Cdk1 which
lacks the inhibitory phosphorylation sites. Secondly, phos-
phorylation on Thr14 and Tyr15 was not observed in the
in vitro assays in which Rux was able to inhibit kinase
activity. The mechanism of Cdk1 inhibition by Rux also
does not rely on preventing Cyc–Cdk1 complex forma-
tion. We found no significant change in the level of cyclins
coprecipitating with Cdk1 in the presence of Rux. We did,
however, find markedly reduced levels of Thr161 phos-
phorylation both after expression in vivo and in the in vitro
experiments. Phosphorylation of Thr161 in the T-loop is
carried out by a CAK [26]. Rux could influence the level
of Thr161 phosphorylation in several ways. First, Rux
could have a Thr161-dephosphorylating activity. This is
unlikely as Rux is not able to change the state of Thr161
phosphorylation when added after the initial Thr161-
phosphorylation event. The second possibility is that Rux
inhibits CAK activity directly. Rux prevents Thr161 phos-
phorylation by two very different CAKs, however. In one
case, we used a monomeric kinase, CIV1, the in vivo CAK
in S. cerevisiae [21,23,27]. The other source of CAK was a
crude Drosophila extract that contained CycH–Cdk7.
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Embryos lacking Cdk7 activity did not provide CAK activ-
ity (data not shown), indicating that the CAK activity in
our extracts depends on CycH–Cdk7 activity. CIV1 and
CycH–Cdk7 are very different in nature; therefore, it is
very unlikely that Rux can inhibit both kinase activities.
Finally, should Rux function by inhibiting CAK we would
expect to see an inhibition of Cdk2–CycE by Rux, which
is not the case in our in vitro assays. Instead, Rux might
prevent CAK access to the T-loop or recognition of
Cyc–Cdk complexes by CAK. Rux does not act solely by
preventing Thr161 phosphorylation, however, as it also is
able to inhibit activated, Thr161-phosphorylated Cdk1
kinase activity. The molecular nature of this inhibition is
at present not known. In summary, Rux can inhibit kinase
activity by at least two mechanisms: prevention of Thr161
phosphorylation and inhibition of active Cyc–Cdk com-
plexes. Such dual effects have previously been described
for a number of CKIs [28–30].
The inhibition of kinase activity by Rux in vitro occurred
in a progressive fashion when using CycB–Cdk1, but a
more complex effect on CycA–Cdk1 was observed. The
addition of small amounts of Rux resulted in a stimulation
of kinase activity and only larger amounts resulted in an
inhibition. The increase in activity was not associated with
an increase in Cyc–Cdk1 association or Thr161 phospho-
rylation. The seemingly contradictory ability of CKIs to
enhance the activity of Cyc–Cdk complexes has previ-
ously been described for members of the CIP/KIP family
[7,31,32]. How Rux stimulates activity in this situation
remains to be resolved. Several explanations are possible.
Rux could have a chaperone-type function for CycA, or
different stoichiometric configurations of Rux and cyclins
might exist that can be either stimulatory or inhibitory.
Finally, Rux might contain several binding sites with dif-
ferent affinities whose effect on CycA might be qualita-
tively different. 
It has been suggested previously that Rux acts by targeting
mitotic cyclins for destruction [13]. CycA destruction is not
a necessary component of Rux function, however. Rux pre-
vents the S-phase-inducing activity of a non-destructible
CycA (CycA∆170) in vivo [10] and it can inhibit kinase
activity stimulated by CycA∆170 in vitro. Cyclin degrada-
tion in G1 is caused by fizzy-related/HCT1-dependent
anaphase-promoting complex (APC) activity [33]. This
function in turn is downregulated by Cyc–Cdk activity
[34]. Thus, by inhibiting Cdk1 kinase activity, Rux  may
contribute towards maintaining a G1 by keeping APC
activity high and causing cyclin degradation. Disappear-
ance of mitotic cyclins was also described when Rux was
expressed during S and G2 phases [13]. We repeated these
experiments by expressing Rux in paired stripes in the
embryo and also followed CycA disappearance after heat-
shock expression of Rux. In both cases, CycA disappear-
ance was only observed after a considerable time (3 hours
after Rux expression). Embryos of this age are older than
7 hours and would normally prepare to enter G1 of cycle
17, a stage when CycE is downregulated and fizzy-related
is upregulated in the epidermis. These changes, and not
the presence of Rux, most likely lead to the ‘eventual dis-
appearance’ [13] of CycA.
Inhibition by Rux also does not rely on changes in the
subcellular distribution of cyclins. Although both CycA
and CycB moved to the nucleus upon Rux expression,
mitosis could still be suppressed when a mutant form of
Rux lacking the NLS was expressed and no CycA accu-
mulation in the nucleus was observed. The presence of
Rux in the nucleus would, however, be advantageous in
protecting the nucleus from S-phase-inducing
CycA–Cdk1 activity during G1.
Conclusions
To our knowledge, Rux is the first CKI to be reported in a
multicellular organism that is specific for mitotic cyclins.
As similar CKIs have been identified in unicellular
eukaryotes, such as SIC1 from S. cerevisiae [35] and rum1
from Schizosaccharomyces pombe [36], there may be an evo-
lutionarily conserved requirement for an activity which
keeps mitotic cyclins in check during G1 [37]. 
During the G1 state, cyclin turnover is high, resulting in
low mitotic cyclin levels. At this stage, even low levels of
Rux are high relative to cyclins and Rux can prevent
Cyc–Cdk1 kinase activity by interfering with Thr161
phosphorylation and inhibiting Cyc–Cdk1 kinase activity.
As such, Rux is a typical CKI involved in control of the G1
state. As the cell progresses through G1 CycE levels rise.
Rux is a substrate for CycE–Cdk2, and CycE has been
shown to promote Rux turnover [13]. Thus, while CycE
levels rise, Rux levels decrease, and switching off APC
activity at the G1–S transition allows CycA levels to rise.
At this stage, the ability of small amounts of Rux to
enhance CycA–Cdk1 kinase activity may have a physio-
logical relevance. It is conceivable that low levels of Rux
enhance any S-phase and/or mitotic functions of CycA by
increasing CycA–Cdk1 kinase activity and promoting their
transport to the nucleus.
Materials and methods
Drosophila stocks, heat-shock procedure and embryonic
extracts
The hs–rux, hs–cycA, hs–Cdc2AF and hs–stg flies have been described
previously [10,13,16,38]. The wild-type strain used was OregonR. The
heat-shock procedure and RNA injections were performed as described
[10,39]. Embryonic extracts were prepared as described [19] and typi-
cally have a protein concentration around 35 mg/ml.
DNA constructs and in vitro translation
All constructs were cloned in an SP64-based vector containing the
Xenopus β-globin 5′ leader sequence. HA–Cdk1 (pSF191), CycB∆46
(pSF283) and CycA∆170 (pSF281) have been described [10,17]. Rux
(pSF821) contains the coding region from the rux cDNA [11] flanked by
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the Xenopus β-globin 3′ and 5′ untranslated regions. HA–Rux (EF018)
was constructed by cloning the coding region of pSF821 into the vector
pSF398, which contains the HA tag. CycE (pSF828) was obtained by
cloning the CycE type I cDNA [40] into the vector pSF036 containing
the 5′ Xenopus β-globin region. HA–Cdk2 (pSF905) was cloned by
PCR amplification using the Dmcdc2c cDNA [41] and oligonucleotides
that contained the coding sequence of the HA tag. Transcription in vitro
and translation in reticulocyte lysate (Promega) were performed as
described [39] using Expre35S35S-protein labeling mix from NEN.
Antibodies, immunofluorescence, immunoprecipitations and
immunoblotting
Rux antibody was made by immunizing rats with bacterially produced
GST–Rux, which had been purified with glutathione–Sepharose beads
(Pharmacia). Antibodies against CycA, CycB and Cdk1 have been
described [10,38]. The antibodies against β-tubulin, HA and PSTAIRE
were obtained from Amersham, Boehringer Mannheim and Sigma,
respectively. The anti-Even-skipped antibody was provided by Manfred
Frasch. The PSTAIRE antibody recognizes Drosophila Cdk1 100 times
better than Drosophila Cdk2 [42]. Secondary antibodies were
obtained from Dianova. For immunoprecipitations, embryonic extract
was incubated with 10 µl protein G–Sepharose beads (Pharmacia)
and 15 µl Rux antibody for 2 h at 4°C. The immunoprecipitate was then
washed twice in immunoprecipitation buffer (IP buffer: 10 mM Tris
pH 7.5, 80 mM K-β-glycerophosphate pH 7.3, 20 mM EGTA pH 8.0,
15 mM MgCl2, 0.5 mM DTT, 2 mM Na3VO4, 10% glycerol). The super-
natant was removed, the beads resuspended in 20 µl loading buffer,
boiled for 5 min and proteins separated by SDS–PAGE. The gel was
blotted onto nitrocellulose, western blots performed and developed
using the ECL system (Amersham).
Histone H1 kinase assays
Proteins were translated individually, mixed and each sample brought
to an equal volume using rabbit reticulocyte lysate. The mixture was
incubated to allow complex formation and Cdk1 phosphorylation on
Thr161 by the addition of CAK, 10 mM MgCl2 and 2 mM ATP for
30 min at room temperature. As a source of CAK, approximately 35 µg
bacterially produced GST–CIV1p (kindly provided by M. Mann) [21],
which had been purified with glutathione–Sepharose beads (Pharma-
cia), or 8 µl extract prepared from 0–1 h old wild-type embryos was
used. After mixing of all components, an aliquot was removed and ana-
lyzed by SDS–PAGE and autoradiography to visualize the presence
and abundance of the different translation products (input gel). For
immunocomplex histone H1 kinase assays, HA–Cdks were immuno-
precipitated for 2 h at 4°C in 300 µl IP buffer, containing 20 mM EDTA,
10 µl protein G–Sepharose beads (Pharmacia) and 1.5 µg anti-HA
antibody. The beads were washed twice in 300 µl IP buffer and then
split into two equal fractions. One half was analyzed by high-resolution
(25 cm) SDS–PAGE and autoradiography to visualize the levels of
coprecipitated cyclins and to allow distinction of Cdk phosphoiso-
forms. The second half was washed twice in 300 µl pre-kinase buffer
(25 mM HEPES pH 7.4, 10 mM MgCl2, 1 mM DTT and 25 µM ATP).
The supernatant was removed and the beads gently resuspended in
histone H1 kinase assay buffer (25 mM HEPES pH 7.4, 10 mM MgCl2,
10 µM ATP, 250 µg/ml histone H1 and 3 mCi/ml [γ-32P]ATP). Kinase
reactions were incubated for 30 min at room temperature, stopped by
adding an equal volume of sample buffer and analyzed by SDS–PAGE
followed by autoradiography and phosphorimaging; 32P intensities are
displayed as percentage of kinase activity normalized to a positive
control. Kinase assays from embryo extract were performed as above
with the exception that the embryos were first homogenized in HB
buffer and Cdk1 was immunoprecipitated with a polyclonal anti-Cdk1
antiserum for 2 h at 4°C in IP buffer. Direct kinase assays in Figure 5
were performed by incubating reticulocyte-translated proteins directly
with 250 µg/ml histone H1 and 3 mCi/ml [γ-32P]ATP.
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